What Is EPS Innovative Medicine?EPS Innovative Medicine interfaces between academia /bio-venture companies and markets to facilitate early launch of potential drugs.

We create a new drug discovery platform connecting Japan and Asia

Many Japanese drug development venture companies are confronted with problems in obtaining know-how related to clinical development in general, the networking needed to expand their business overseas, and how to fund-raise for development. Overseas drug development ventures find it difficult to understand the application process required for approval before they enter the Chinese and Japanese markets.
EPS innovative medicine (Japan) LTD. (hereinafter; EPS innovative medicine), a leading contract research organization (CRO) within EPS, provides drug development venture companies with one-stop support for clinical development. We can increase the value of seed compounds and facilitate out-licensing and marketing through our network in Japan and China. Together with SMO and CSO, CRO plays an important part in developing and distributing pharmaceuticals.
We interface between Japanese, American and European bio-venture enterprises and the Japanese and Asian markets to facilitate the early launch of potential drugs.
To this end, we are creating a new drug discovery platform.

European bio-ventures, Japanese and Asian markets, Japanese bio-ventures, American bio-ventures

Our business model

1Our original development model

Our original development model

EPS Innovative Medicine develops seed compounds it has discovered, and those possessed by drug development joint venture (JV) subsidiaries of EPS Innovative Medicine. We produce and market these in Japan and overseas, particularly China.

2License fee model

License fee model

EPS Innovative Medicine obtains official permission to develop seed compounds owned by bio-ventures (in-licensing) and engages in clinical development. We use the EPS group to increase the value of seed compounds and out-license them to Japanese and Chinese partner companies.

3Licensing mediation model

licensing mediation model

EPS Innovative Medicine obtains official permission to develop seed compounds owned by bio-ventures (in-licensing) and out-licenses them to Japanese and Chinese partner companies that appreciate their value through its network.

4iCRO(Innovative CRO)

iCRO(Innovative CRO)

EPS Innovative Medicine collaborates with the EPS Group to provide one-stop total solutions to situations ranging from development to marketing. We accept pay-for-performance contracts.

One-stop solutions by EPS Innovative Medicine

One-stop solutions by EPS Innovative Medicine

※Pinch out

Contact Us

Please feel free to contact us.